Jasper Therapeutics Inc
NASDAQ:JSPR
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Jasper Therapeutics Inc
NASDAQ:JSPR
|
US |
|
Fisher & Paykel Healthcare Corporation Ltd
F:FPLB
|
NZ |
|
C
|
Chugai Pharmaceutical Co Ltd
DUS:CUP
|
JP |
|
Schindler Holding AG
F:SHRQ
|
CH |
|
Lemonade Inc
F:LE0
|
US |
|
E
|
Enanta Pharmaceuticals Inc
F:9EP
|
US |
|
Vera Bradley Inc
F:ELI
|
US |
Intrinsic Value
Is JSPR undervalued or overvalued?
See the intrinsic value estimate for Jasper Therapeutics Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
JSPR looks undervalued.
But is it cheap by its own standards?
See how today’s valuation compares with JSPR’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What Jasper Therapeutics Does
Jasper Therapeutics is a biotechnology company developing antibody-based medicines, with its lead program built around briquilimab, an antibody that targets the c-Kit receptor on stem cells and mast cells. The company is trying to use that biology in two main ways: to help prepare patients for stem cell transplant without traditional chemotherapy, and to treat diseases driven by mast cells, such as certain allergic and inflammatory conditions. Its main customers would be hospitals, transplant centers, and specialist doctors if its drugs reach the market.
- Headquarters
- United States of America US
- Employees
- 22
- IPO date
- Nov 20, 2019
Earnings Waterfall
Jasper Therapeutics Inc
The intrinsic value for Jasper Therapeutics Inc (JSPR) under the Base Case is hidden USD.
Compared with the current market price of 0.51 USD, the stock appears hidden.